Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer

Oncogenic mutations in the gene KRAS are commonly detected in non-small cell lung cancer (NSCLC). This disease is inherently difficult to treat, and combinations involving platinum-based drugs remain the therapeutic mainstay. In terms of novel, pharmacologically actionable targets, nitric oxide synt...

Descripción completa

Detalles Bibliográficos
Autores principales: Pershing, Nicole L.K., Yang, Chi-Fu J., Xu, MengMeng, Counter, Christopher M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173142/
https://www.ncbi.nlm.nih.gov/pubmed/27285753
http://dx.doi.org/10.18632/oncotarget.9874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173142/
https://www.ncbi.nlm.nih.gov/pubmed/27285753
http://dx.doi.org/10.18632/oncotarget.9874

Ejemplares similares